Skip to main content
OpenTrials
Completed

NCT Number: NCT02084693

COMPREHENSIVE® REVERSE SHOULDER Mini BasePlate

Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.

Completed

Looking for future studies?

Notify Me

Key information

Age range

60 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Bunndang Seoul Nat'l Univ. Hospital, Seongnam-si, Seongnam, South Korea

Loading trial locations.

About this study

The primary objective of this prospective clinical data collection is to evaluate survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate. Secondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes including adverse events, scapular notching, and Constant Score.

All shoulders on which data will be collected are legally marketed and none of the devices are investigational or experimental. FDA has cleared this device via Premarket Notification 510(k) K080642. This data collection effort will document the clinical outcomes of the Comprehensive® Reverse shoulders. The data gathered will be collated and used to provide feedback to designing engineers, support marketing efforts, and answer potential questions from reimbursement agencies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients / cases to be included in this study shall utilize the following inclusion criteria:

  • Comprehensive Reverse Shoulder Mini Base Plate and Mini Stem in a reverse shoulder configuration.
  • The patient must be anatomically and structurally suited to receive the implants and a functional deltoid muscle is necessary.
  • Grossly deficient rotator cuff with severe arthropathy and/or
  • Previously failed shoulder joint replacement with a grossly deficient rotator cuff.
  • Primary total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency, or
  • Fracture total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency, or
  • Revision total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency.

Exclusion criteria

  • The exclusion criteria are the same as the indications stated in the cleared labeling for the device:

Absolute contraindications include infection, sepsis, and osteomyelitis.

Relative contraindications include:

  • Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions.
  • Osteoporosis.
  • Metabolic disorders which may impair bone formation.
  • Osteomalacia.
  • Distant foci of infections which may spread to the implant site.
  • Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram.

Treatment and study plan

COMPREHENSIVE

Device

Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.

Primary outcomes

  1. Survivorship

    Time frame: 1 year

    The primary objective of this prospective clinical data collection is to evaluate survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.

Secondary outcomes

  1. Adverse Events (including dislocation)

    Time frame: 3 year

    Secondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes

  2. Constant-Murley Shoulder Score

    Time frame: 3 year

    Secondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes

  3. Radiographic Evaluation (Plain X-ray and CT)

    Time frame: 3 year

    Secondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes

  4. Scapular Notching

    Time frame: 3 year

    Secondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes

  5. Constant-Murley Shoulder Score

    Time frame: 1 year

    Secondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes

  6. Constant-Murley Shoulder Score

    Time frame: 6 Months

    Secondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes

  7. Radiographic Evaluation

    Time frame: 1 year

    Secondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes

  8. Radiographic Evaluation

    Time frame: 6 Weeks

    Secondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes

Sponsors and collaborators

Lead sponsor

Zimmer Biomet

Industry

Registry information

Official study title

Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.

Important dates

Study start
2013
Primary completion
2019
Study completion
2019
First posted
Mar 12, 2014
Registry last updated
Jul 5, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.